Ftse Mib
34.490,71
0,07%
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
NASDAQ
16.920,79
1,10%
Bitcoin
68.917,78
0,56%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Biocept Inc (BIOC) Biocept Inc (BIOC) Notizie

BIOC

Biocept (BIOC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BIOC
DataOraFonteTitoloSimboloCompagnia
20/10/202312:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIOCBiocept Inc
21/09/202314:00Business WireEnrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal MetastasesNASDAQ:BIOCBiocept Inc
08/09/202314:00Business WireBiocept Signs CNSide™ Licensing Agreement with Plus TherapeuticsNASDAQ:BIOCBiocept Inc
05/09/202314:00Business WireBiocept to Participate in the H.C. Wainwright Global Investment ConferenceNASDAQ:BIOCBiocept Inc
25/08/202314:00Business WireBiocept to Hold Business Update Conference Call on August 30, 2023NASDAQ:BIOCBiocept Inc
14/08/202322:05Business WireBiocept Reports Second Quarter 2023 Financial ResultsNASDAQ:BIOCBiocept Inc
14/08/202314:00Business WireBiocept’s CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer ConferenceNASDAQ:BIOCBiocept Inc
14/07/202300:15Business WireBiocept Announces the Passing of Board Chair M. Faye WilsonNASDAQ:BIOCBiocept Inc
21/06/202322:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BIOCBiocept Inc
21/06/202301:10Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:BIOCBiocept Inc
20/06/202322:15Business WireBiocept Names Antonino Morales as President and Chief Executive OfficerNASDAQ:BIOCBiocept Inc
14/06/202322:05Business WireBiocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023NASDAQ:BIOCBiocept Inc
05/06/202314:00Business WireScientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept’s CNSide™ Versus CytologyNASDAQ:BIOCBiocept Inc
25/05/202312:04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:BIOCBiocept Inc
25/05/202302:39Business WireBiocept Announces Pricing of $5.0 Million Underwritten Public OfferingNASDAQ:BIOCBiocept Inc
23/05/202314:18Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:BIOCBiocept Inc
17/05/202314:00Business WireBiocept Announces One-for-Thirty Reverse Stock SplitNASDAQ:BIOCBiocept Inc
10/05/202322:05Business WireBiocept Reports First Quarter 2023 Financial ResultsNASDAQ:BIOCBiocept Inc
21/04/202314:31Edgar (US Regulatory)Revised Proxy Soliciting Materials (definitive) (defr14a)NASDAQ:BIOCBiocept Inc
20/04/202322:07Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:BIOCBiocept Inc
17/04/202322:10Business WireBiocept Reports 2022 Financial ResultsNASDAQ:BIOCBiocept Inc
17/04/202322:04Edgar (US Regulatory)Amended Quarterly Report (10-q/a)NASDAQ:BIOCBiocept Inc
03/04/202314:01Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:BIOCBiocept Inc
24/03/202313:00Business WireEnrollment Begins in FORESEE Clinical Trial Using Biocept’s CNSide™ to Evaluate Patients with Leptomeningeal MetastasesNASDAQ:BIOCBiocept Inc
01/03/202314:00Business WireBiocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BIOCBiocept Inc
06/01/202312:55Business WireBiocept to Explore Strategic Alternatives and Implement Restructuring PlanNASDAQ:BIOCBiocept Inc
21/11/202222:12Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BIOCBiocept Inc
21/11/202222:05Business WireBiocept Reports Third Quarter 2022 Financial ResultsNASDAQ:BIOCBiocept Inc
18/11/202214:00Business WireBiocept Appoints Financial Executive Quyen Dao-Haddock to its Board of DirectorsNASDAQ:BIOCBiocept Inc
16/11/202214:00Business WireBiocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous SystemNASDAQ:BIOCBiocept Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BIOC

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
TIT
Telecom Italia
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
STMMI
ST Microelectronics
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TEN
Tenaris
BIT
RACE
Ferrari NV
BIT
SPM
Saipem
BIT
BAMI
Banco BPM
BIT
PRY
Prysmian
BIT
BPE
Bper Banca
BIT
TITR
Telecom Italia
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network